pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 29·1 min read
save

Most-wanted fugitive Ronald Fischer operated under alias in biotech industry for two decades

Jul 29, 2026·read at STAT ↗Negative

A Rhode Island man on the most-wanted list was recently uncovered as a hidden employee in the biotech sector, having worked under a false identity for about twenty years.

The individual, identified as Ronald Fischer, used the alias Richard Graydon and presented fabricated curricula vitae. He had previously been convicted of sexual assault before disappearing and remaining at large.

During his time in the industry, Fischer was employed full‑time by at least one biotech firm and on a contractual basis by two large pharmaceutical companies, despite the lack of thorough background checks.

The revelation sparked shock among industry observers, though a recruiter familiar with the case noted that the deception was not entirely unexpected given the circumstances.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: In the biotech industry, a most-wanted fugitive was long hiding in plain sight”

read at STAT ↗
555 words · retrieved Jul 29
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADINGPATH
topics
Oncology2DermatologyMelanoma

related stories

  • 18h agoSanofi cuts 229 Blueprint Medicines employeesBioSpace
  • Jul 29Opinion: The VA could help America win the biotechnology race with ChinaSTAT
  • Jul 28STAT+: American Diabetes Association, facing calls for resignations, asks for patienceSTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Aug 10Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 pushFierce Biotech